In the latest trading session, Gilead Sciences (GILD) closed at $89.14, marking a -1.64% move from the previous day.

After the separation, Gilead will hold around 25% of the outstanding shares in both Galapagos and the spin-off company. While ...

This was the stock's fourth consecutive day of losses.

This was the stock's fifth consecutive day of losses.

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.10% of ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

TCW Funds, an investment management company, released its “TCW Relative Value Large Cap Fund” Q3 2024 investor letter. A copy ...

We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...

RBC Capital analyst Brian Abrahams lowered the firm’s price target on Gilead (GILD) to $83 from $84 and keeps a Sector Perform rating on the ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...